Galleria mellonella as an Antimicrobial Screening Model

Area of Science:

• Microbiology
• Infectious Diseases
• Drug Development

Background:

• Antibiotic resistance is a growing global health crisis, necessitating rapid development of new antimicrobial drugs.
• Current preclinical drug development is inefficient, with many candidates failing during clinical trials.
• There is a need for standardized, accessible, and cost-effective models to improve preclinical antimicrobial development.

Purpose of the Study:

• To describe a standardized methodology for optimizing the Galleria mellonella (greater wax moth) larvae infection model for preclinical antimicrobial testing.
• To provide a reproducible protocol for evaluating antimicrobial efficacy in vivo.
• To reduce reliance on mammalian models in early-stage drug discovery.

Main Methods:

• The study outlines a standardized protocol for using Galleria mellonella larvae as an infection model.
• Methodology includes recommendations for experimental setup, sample preparation, and infection/treatment protocols.
• Pseudomonas aeruginosa, a WHO priority pathogen, was used as an exemplar to demonstrate the protocol.

Main Results:

• The Galleria mellonella model provides a biologically relevant alternative to in vitro screens and reduces the need for mammalian models.
• Standardized protocols enhance reproducibility in assessing microbial virulence and antimicrobial compound efficacy.
• The model facilitates preliminary in vivo evaluation of novel antimicrobial therapeutics.

Conclusions:

• Implementing standardized Galleria mellonella infection models can streamline preclinical antimicrobial development pipelines.
• This approach can decrease the number of ineffective compounds entering clinical trials, thereby increasing development efficiency.
• Optimized G. mellonella models contribute to combating antibiotic resistance by accelerating the discovery of effective treatments.